[go: up one dir, main page]

WO2006034510A3 - Compositions enantiomeres de cicletanine, seules ou combinees a d'autres agents, utilisees a des fins therapeutiques - Google Patents

Compositions enantiomeres de cicletanine, seules ou combinees a d'autres agents, utilisees a des fins therapeutiques Download PDF

Info

Publication number
WO2006034510A3
WO2006034510A3 PCT/US2005/034763 US2005034763W WO2006034510A3 WO 2006034510 A3 WO2006034510 A3 WO 2006034510A3 US 2005034763 W US2005034763 W US 2005034763W WO 2006034510 A3 WO2006034510 A3 WO 2006034510A3
Authority
WO
WIPO (PCT)
Prior art keywords
cicletanine
combination
disease
agents
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/034763
Other languages
English (en)
Other versions
WO2006034510A2 (fr
Inventor
Glenn Cornett
Jim Page
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/035,308 external-priority patent/US20060153934A1/en
Priority claimed from US11/035,328 external-priority patent/US20060154959A1/en
Priority claimed from US11/035,231 external-priority patent/US20060154971A1/en
Priority claimed from US11/232,724 external-priority patent/US20060089374A1/en
Application filed by Individual filed Critical Individual
Priority to EP05800096A priority Critical patent/EP1804795A4/fr
Priority to CA002581337A priority patent/CA2581337A1/fr
Publication of WO2006034510A2 publication Critical patent/WO2006034510A2/fr
Publication of WO2006034510A3 publication Critical patent/WO2006034510A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Dans des modes de réalisation préférés, la présente invention concerne des médicaments thérapeutiques et des combinaisons de médicaments ainsi que des méthodes connexes pour le traitement et/ou la prévention de complications pouvant survenir chez des patients souffrant de diabète, d'un syndrome du métabolisme et/ou d'hypertension. Plus particulièrement, certains aspects de l'invention concernent l'utilisation de la ciclétanine comme monothérapie ou en combinaison avec d'autres agents pour le traitement de la maladie. Qu'elle soit utilisée en monothérapie ou en combinaison avec d'autres médicaments, la ciclétanine peut se présenter sous la forme d'un mélange non racémique d'énantiomères négatifs (-) et positifs (+) de ciclétanine, ou bien sous la forme de l'énantiomère (-) ou (+) seul.
PCT/US2005/034763 2004-09-22 2005-09-22 Compositions enantiomeres de cicletanine, seules ou combinees a d'autres agents, utilisees a des fins therapeutiques Ceased WO2006034510A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05800096A EP1804795A4 (fr) 2004-09-22 2005-09-22 Compositions enantiomeres de cicletanine, seules ou combinees a d'autres agents, utilisees a des fins therapeutiques
CA002581337A CA2581337A1 (fr) 2004-09-22 2005-09-22 Compositions enantiomeres de cicletanine, seules ou combinees a d'autres agents, utilisees a des fins therapeutiques

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US61232304P 2004-09-22 2004-09-22
US61236904P 2004-09-22 2004-09-22
US60/612,369 2004-09-22
US60/612,323 2004-09-22
US11/035,308 2005-01-13
US11/035,308 US20060153934A1 (en) 2005-01-13 2005-01-13 Combination therapies of cicletanine and magnesium
US11/035,328 US20060154959A1 (en) 2005-01-13 2005-01-13 Combination therapies of cicletanine and carvedilol
US11/035,328 2005-01-13
US11/035,231 US20060154971A1 (en) 2005-01-13 2005-01-13 Combination therapies of cicletanine and lacidipine
US11/035,231 2005-01-13
US68468405P 2005-05-26 2005-05-26
US60/684,684 2005-05-26
US11/232,724 2005-09-21
US11/232,724 US20060089374A1 (en) 2003-07-17 2005-09-21 Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease

Publications (2)

Publication Number Publication Date
WO2006034510A2 WO2006034510A2 (fr) 2006-03-30
WO2006034510A3 true WO2006034510A3 (fr) 2006-06-01

Family

ID=36090724

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/034763 Ceased WO2006034510A2 (fr) 2004-09-22 2005-09-22 Compositions enantiomeres de cicletanine, seules ou combinees a d'autres agents, utilisees a des fins therapeutiques

Country Status (3)

Country Link
EP (1) EP1804795A4 (fr)
CA (1) CA2581337A1 (fr)
WO (1) WO2006034510A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
TWI513462B (zh) * 2009-11-13 2015-12-21 Toray Industries 糖尿病之治療或預防藥

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383998A (en) * 1981-02-10 1983-05-17 Societe De Conseils De Recherches Et D'applications Scientifiques Furo-(3,4-c)-pyridine derivatives and their pharmaceutical use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2148082A1 (fr) * 1993-09-03 1995-03-09 Daisuke Machii Derives d'imidazoquinazoline
HUP0300990A2 (hu) * 2003-04-15 2005-05-30 SynoSens Kutató és Fejlesztő Kft. Szinergista gyógyszer-kombináció a diabetesz megelőzésére vagy kezelésére
WO2005009446A1 (fr) * 2003-07-17 2005-02-03 Cotherix, Inc. Polytherapies destinees au traitement de l'hypertension et de complications chez des patients souffrant de diabetes ou du syndrome metabolique
US20050113314A1 (en) * 2003-08-29 2005-05-26 Fong Benson M. Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383998A (en) * 1981-02-10 1983-05-17 Societe De Conseils De Recherches Et D'applications Scientifiques Furo-(3,4-c)-pyridine derivatives and their pharmaceutical use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1804795A4 *

Also Published As

Publication number Publication date
EP1804795A2 (fr) 2007-07-11
WO2006034510A2 (fr) 2006-03-30
CA2581337A1 (fr) 2006-03-30
EP1804795A4 (fr) 2007-11-07

Similar Documents

Publication Publication Date Title
EP1933833B8 (fr) Therapie pour le traitement de la vessie hyperactive
EP2371853A3 (fr) Dérivés d'insuline ou ses sels pharmaceutiquement acceptables, composition pharmaceutique, utilisation du dérivé d'insuline et son sel pharmaceutiquement acceptable et procédé de traitement
EP2168962A3 (fr) Phénylacétamides et leur utilisation en tant que modulateurs de la glucokinase
EP2526933A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
MY143795A (en) Tetrahydropyridoindole derivatives
WO2006034373A8 (fr) Variants et variants chimiquement modifies de phenylalanine ammonia-lyase
WO2007137247A3 (fr) Traitement de troubles dépressifs
WO2005037798A3 (fr) Nouveaux composés
WO2006017188A3 (fr) Traitement adjuvant d’antipsychotiques atypiques à base de memantine dans des cas de schizophrénie
WO2006070325A3 (fr) Derives de 2,3,4,9-tetrahydro-1h-carbazole utilises en tant qu'antagonistes des recepteurs de crth2
WO2005086656A3 (fr) Derives d'heteroarylaminopyrazole utilises pour traiter le diabete
EP2392322A3 (fr) Schemas posologiques pour le trans-clomiphene
WO2004096118A3 (fr) Composition permettant d'ameliorer la cognition et la memoire
WO2008032222A3 (fr) Traitement des vertiges avec de l'acétyl-l-leucine
WO2006034510A3 (fr) Compositions enantiomeres de cicletanine, seules ou combinees a d'autres agents, utilisees a des fins therapeutiques
WO2008085872A8 (fr) Ciclétanine et inhibiteurs de pkc pour traiter les troubles cardiaques et pulmonaires
WO2007056454A3 (fr) Utilisation de cicletanine et d'autres furopyridines dans le traitement de l'hypertension a predominance systolique, l'hypertension systolique isolee, du pouls eleve et de l'hypertension generale
GB0606001D0 (en) Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome
WO2005092878A3 (fr) Analogues de schweinfurthines
WO2006064228A3 (fr) Composes
EP1033133A4 (fr) Composition pour le traitement du diabete et procede de traitement du diabete
WO2005120518A3 (fr) Utilisation d'analogues d'atp pour le traitement des maladies cardio-vasculaires
WO2006012438A3 (fr) Compositions et procedes de traitement et de prevention de la resistance a l'insuline
EA200970877A1 (ru) Композиция, пригодная для предупреждения диабета 2 типа и его осложнений у пациентов с предиабетом с резистентностью к инсулину
WO2006128035A3 (fr) Compositions enantiomeres de cicletanine, combinees a d'autres agents, pour le traitement de l'hypertension

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2581337

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 3003/DELNP/2007

Country of ref document: IN

Ref document number: 2005800096

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005800096

Country of ref document: EP